Content
March 2018, Volume 2, Issue 1
- 5-17 Application of Discrete-Choice Experiment Methods in Tobacco Control: A Systematic Review
by Kabindra Regmi & Dinesh Kaphle & Sabina Timilsina & Nik Annie Afiqah Tuha - 19-29 Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
by Graeme Ball & Feng Xie & Jean-Eric Tarride - 31-41 Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data
by Jacqueline Nicholas & Aaron Boster & Ning Wu & Wei-Shi Yeh & Monica Fay & Jon Kendter & Ming-Yi Huang & Andrew Lee - 43-51 Weighting Health Outcomes by Socioeconomic Position Using Stated Preferences
by Anita Lal & Mohammad Siahpush & Marjory Moodie & Anna Peeters & Robert Carter - 53-61 Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
by Ahva Shahabi & Desi Peneva & Devin Incerti & Kimmie McLaurin & Warren Stevens - 63-76 An Exploratory Study of Long-Term Publicly Waitlisted Bariatric Surgery Patients’ Quality of Life Before and 1 Year After Bariatric Surgery, and Considerations for Healthcare Planners
by Julie A. Campbell & Martin Hensher & Amanda Neil & Alison Venn & Stephen Wilkinson & Andrew J. Palmer - 77-85 Reliability and Validity of the Greek Migraine Disability Assessment (MIDAS) Questionnaire
by Theodora Oikonomidi & Michail Vikelis & Artemios Artemiadis & George P. Chrousos & Christina Darviri
December 2017, Volume 1, Issue 4
- 233-239 Statistical Alchemy: Conceptual Validity and Mapping to Generate Health State Utility Values
by Jeff Round & Annie Hawton - 241-253 Choosing Between Unicompartmental and Total Knee Replacement: What Can Economic Evaluations Tell Us? A Systematic Review
by Edward Burn & Alexander D. Liddle & Thomas W. Hamilton & Sunil Pai & Hemant G. Pandit & David W. Murray & Rafael Pinedo-Villanueva - 255-263 Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)
by Lisa Masucci & Jaclyn Beca & Mona Sabharwal & Jeffrey S. Hoch - 265-278 Utilization of Intergovernmental Funds to Implement Maternal and Child Health Plans of a Multi-Strategy Community Intervention in Haryana, North India: A Retrospective Assessment
by Madhu Gupta & Federica Angeli & Hans Bosma & Shankar Prinja & Manmeet Kaur & Onno C. P. Schayck - 279-290 Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden
by Ugne Sabale & Mattias Ekman & Daniel Thunström & Claire Telford & Christopher Livings - 291-300 Eliciting the Monetary Value of a Quality-Adjusted Life Year in a Greek Outpatient Department in Times of Economic Austerity
by A. Mavrodi & V. Aletras & A. Spanou & D. Niakas - 301-314 Development of a Procedure for the Government Provision of Bone-Anchored Prosthesis Using Osseointegration in Australia
by Laurent Frossard & Gregory Merlo & Tanya Quincey & Brendan Burkett & Debra Berg
September 2017, Volume 1, Issue 3
- 145-147 Can Price Transparency Contribute to More Affordable Patient Access to Medicines?
by Sabine Vogler & Kenneth R. Paterson - 149-165 Model-Based Economic Evaluation of Treatments for Depression: A Systematic Literature Review
by Spyros Kolovos & Judith E. Bosmans & Heleen Riper & Karine Chevreul & Veerle M. H. Coupé & Maurits W. Tulder - 167-173 Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology
by Kavisha Jayasundara & Murray Krahn & Muhammad Mamdani & Jeffrey S. Hoch & Paul Grootendorst - 175-184 Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II–III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial
by Abualbishr Alshreef & Allan J. Wailoo & Steven R. Brown & James P. Tiernan & Angus J. M. Watson & Katie Biggs & Mike Bradburn & Daniel Hind - 185-194 Evaluating the Treatment Costs for Uncomplicated Malaria at a Public Healthcare Facility in Nigeria and the Implications
by Charles C. Ezenduka & Daniel Resende Falleiros & Brian B. Godman - 195-202 Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib
by Jörg Mahlich & Shinichiro Okamoto & Akiko Tsubota - 203-221 Health System Efficiency: A Fragmented Picture Based on OECD Data
by Andreas Behr & Katja Theune - 223-229 Cost-Minimisation Analysis of Erythropoiesis-Stimulating Agents in the Treatment of Anaemia in Dialysed Patients: A Pilot Study
by Astrid Darsonval & Virginie Besson & Claire Cavalin
June 2017, Volume 1, Issue 2
- 73-77 Model Registration: A Call to Action
by Christopher James Sampson & Tim Wrightson - 79-97 Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations
by Andrea Gabrio & Alexina J. Mason & Gianluca Baio - 99-108 Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process
by Eva Kaltenthaler & Christopher Carroll & Daniel Hill-McManus & Alison Scope & Michael Holmes & Stephen Rice & Micah Rose & Paul Tappenden & Nerys Woolacott - 109-115 A Comparison of Inpatient Cost Per Day in General Surgery Patients with Type 2 Diabetes Treated with Basal-Bolus versus Sliding Scale Insulin Regimens
by Victoria L. Phillips & Anwar L. Byrd & Saira Adeel & Limin Peng & Dawn D. Smiley & Guillermo E. Umpierrez - 117-121 Cost-Benefit Analysis of Telemedicine Systems/Units in Greek Remote Areas
by Marios-Nikolaos Kouskoukis & Charalambos Botsaris - 123-131 Utilization, Spending, and Price Trends for Quinolones in the US Medicaid Programs: 25 Years’ Experience 1991–2015
by Ziyad S. Almalki & Xiaomeng Yue & Ying Xia & Patricia R. Wigle & Jeff Jianfei Guo - 133-141 Early Assessment of the Likely Cost Effectiveness of Single-Use Flexible Video Bronchoscopes
by Christoffer Lilja Terjesen & Julia Kovaleva & Lars Ehlers - 143-143 Erratum to: Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations
by Andrea Gabrio & Alexina J. Mason & Gianluca Baio
March 2017, Volume 1, Issue 1
- 1-12 The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review
by Blythe Adamson & Dobromir Dimitrov & Beth Devine & Ruanne Barnabas - 13-23 Communal Sharing and the Provision of Low-Volume High-Cost Health Services: Results of a Survey
by Jeff Richardson & Angelo Iezzi & Gang Chen & Aimee Maxwell - 25-36 Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
by Jameel Nazir & Malin Berling & Charles McCrea & Francis Fatoye & Sally Bowditch & Zalmai Hakimi & Adrian Wagg - 37-51 Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model
by Barbara Graaff & Lei Si & Amanda L. Neil & Kwang Chien Yee & Kristy Sanderson & Lyle C. Gurrin & Andrew J. Palmer - 53-63 A Single-Center Cost Analysis of Treating Primary and Metastatic Brain Cancers with Either Brain Laser Interstitial Thermal Therapy (LITT) or Craniotomy
by Eric C. Leuthardt & Jeff Voigt & Albert H. Kim & Pete Sylvester - 65-68 Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review
by Ilke Akpinar & Philip Jacobs & Tien Dat Tran - 69-70 Comment on: “Forecasting Pharmaceutical Prices for Economic Evaluations When There is No Market: A Review”
by Przemysław Holko - 71-71 Authors’ Reply to Holko: “Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review”
by Ilke Akpinar & Philip Jacobs & Dat T. Tran
Printed from https://ideas.repec.org/s/spr/pharmo4.html